10 Pharmaceutical development: From pre-clinical to post approval

Separation Science and Technology

Volumn 8, Issue , 2007, Pages 297-316

  Bynum, Kevin C ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 40649111126     PISSN: 01496395     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0149-6395(07)80016-X     Document Type: Article

References (25)

1. Rao R., and Nagaraju V. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. J. Pharm. Biomed. Anal. 33 (2003) 335-377
2. Entzeroth M. Emerging trends in high-throughput screening. Curr. Opin. Pharmacol. 3 (2003) 522-529
3. Koh H., Yau W., Ong P., and Hegde A. Current trends in modern pharmaceutical analysis for drug discovery. Drug Discov. Today 8 19 (2003) 889-987
4. Kenseth J., and Coldiron S. High-throughput characterization and quality control of small-molecule combinatorial libraries. Curr. Opin. Chem. Biol. 8 (2004) 418-423
5. Xu R., Nemes C., Jenkins K., Rourick R., and Kassel D. Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries. J. Am. Soc. Mass Spectrom. 13 (2002) 155-165
6. Balbach S., and Korn C. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int. J. Pharm. 275 (2004) 1-12
7. Churchwell M., Twaddle N., Meeker L., and Doerge D. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to HPLC-ES/MS/MS. J. Chromatogr. B 825 (2005) 134-143
8. Novakova L., Matysova L., and Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta 68 (2005) 909-918
9. Simmonds E., Lough W., and Gray M. Evaluation of the use of LC-MS in supporting stability studies for preclinical study formulations. J. Pharm. Biomed. Anal. 32 (2003) 1113-1122
10. FDA's policy statement for the development of new stereoisomerism drugs (1992).
11. Snyder L.R., Kirkland J.J., and Glajch J.L. Practical HPLC Method Development. 2nd Edition (1997), Wiley, Rockville
12. Wang X., Li W., and Rasmussen H. Orthogonal method development using hydrophilic interaction chromatography and reversed-phase high-performance liquid chromatography for the determination of pharmaceuticals and impurities. J. Chromatogr. A 1083 (2005) 58-62
13. Marin A., and Barbas C. LC/MS for the degradation profiling of cough-cold products under forced conditions. J. Pharm. Biomed. Anal. 35 (2004) 1035-1045
14. Rao B., Srinivasu M., Kumar K., Bhradwaj N., Ravi R., Mohakhud P., Reddy G., and Kumar P. A stability indicating LC method for Rivastigmine hydrogen tartrate. J. Pharm. Biomed. Anal. 37 (2005) 57-63
15. Nonclinical Laboratory Studies Good Laboratory Practice Regulations. FDA, 21 CFR 58 (2005)
16. (November). Boudreau S., McElvain J., Martin L., Dowling T., and Fields S. Method validation by phase of development an acceptable analytical practice. Pharm. Technol. (2004) 54-66
17. (October). Hariharan M., Ganorkar L., Amidon G., Cavallo A., Gatti P., Hageman M., Choo I., Miller J., and Shah U. Reducing the time to develop and manufacture formulations for first oral dose in humans. Pharm. Technol. (2003) 68-84
18. ICH Q2A. International conference on harmonization: guideline for industry: text on the validation of analytical procedures, availability. Fed. Regist. 60 40 (1995) 11260-11262
19. Food and Drug Administration. Draft guidance for industry on analytical procedures and methods validation chemistry, manufacturing, and controls documentation. Fed. Regist. 65 169 (2000) 52776-52777
20. http://www.fda.gov
21. ICH-Q2A Guideline for Industry. Text on Validation of Analytical Procedures. March (1995)
22. November. ICH-Q2B Guidance for Industry. Validation of Analytical Procedures: Methodology (1996)
23. Etse J. Utility of HPLC as a tool in the transfer of analytical technology. Am. Pharm. Rev. 8 1 (2005) 74-77
24. (October). Majors R. A review of HPLC column packing technology. Am. Lab. (2003) 46-54
25. Spies A., and Dusen V. Counterfeit drugs a menace keeps growing. US Pharmacist 28 (2003) 1